TWI784934B - 抑制lpa之基因表現之組合物及方法 - Google Patents

抑制lpa之基因表現之組合物及方法 Download PDF

Info

Publication number
TWI784934B
TWI784934B TW105131823A TW105131823A TWI784934B TW I784934 B TWI784934 B TW I784934B TW 105131823 A TW105131823 A TW 105131823A TW 105131823 A TW105131823 A TW 105131823A TW I784934 B TWI784934 B TW I784934B
Authority
TW
Taiwan
Prior art keywords
rnai agent
lpa rnai
base
seq
lpa
Prior art date
Application number
TW105131823A
Other languages
English (en)
Chinese (zh)
Other versions
TW201726918A (zh
Inventor
史黛西 梅爾柯斯特
史蒂芬 坎納
大衛 B 羅茲馬
大衛 L 路易士
羅倫 J 阿梅塔
戴倫 H 維克菲爾德
威拉帝摩 Ｓ 初巴斯科伊
濤 裴
李
艾倫 阿梅塔
Original Assignee
美商愛羅海德製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商愛羅海德製藥公司 filed Critical 美商愛羅海德製藥公司
Publication of TW201726918A publication Critical patent/TW201726918A/zh
Application granted granted Critical
Publication of TWI784934B publication Critical patent/TWI784934B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW105131823A 2015-10-01 2016-09-30 抑制lpa之基因表現之組合物及方法 TWI784934B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562235816P 2015-10-01 2015-10-01
US62/235,816 2015-10-01
US201662346304P 2016-06-06 2016-06-06
US62/346,304 2016-06-06
US201662383221P 2016-09-02 2016-09-02
US62/383,221 2016-09-02

Publications (2)

Publication Number Publication Date
TW201726918A TW201726918A (zh) 2017-08-01
TWI784934B true TWI784934B (zh) 2022-12-01

Family

ID=58424351

Family Applications (3)

Application Number Title Priority Date Filing Date
TW105131823A TWI784934B (zh) 2015-10-01 2016-09-30 抑制lpa之基因表現之組合物及方法
TW113106862A TWI880645B (zh) 2015-10-01 2016-09-30 抑制lpa之基因表現之組合物及方法
TW111141660A TWI836693B (zh) 2015-10-01 2016-09-30 抑制ｌｐａ之基因表現之組合物及方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW113106862A TWI880645B (zh) 2015-10-01 2016-09-30 抑制lpa之基因表現之組合物及方法
TW111141660A TWI836693B (zh) 2015-10-01 2016-09-30 抑制ｌｐａ之基因表現之組合物及方法

Country Status (37)

Country Link
US (4) US9932586B2 (enExample)
EP (2) EP4029941A1 (enExample)
JP (4) JP6991966B2 (enExample)
KR (2) KR20240162596A (enExample)
CN (1) CN108368506A (enExample)
AU (3) AU2016331084B2 (enExample)
BR (1) BR112018006489A2 (enExample)
CA (1) CA3000397A1 (enExample)
CL (1) CL2018000803A1 (enExample)
CO (1) CO2018003678A2 (enExample)
CR (1) CR20180231A (enExample)
CY (1) CY1125263T1 (enExample)
DK (1) DK3356529T3 (enExample)
EA (1) EA038478B1 (enExample)
ES (1) ES2896298T3 (enExample)
HR (1) HRP20211410T1 (enExample)
HU (1) HUE055942T2 (enExample)
IL (3) IL300438A (enExample)
JO (2) JOP20210043A1 (enExample)
LT (1) LT3356529T (enExample)
MA (1) MA43347B1 (enExample)
MX (2) MX2018003833A (enExample)
MY (1) MY195796A (enExample)
PE (1) PE20181139A1 (enExample)
PH (1) PH12018500713A1 (enExample)
PL (1) PL3356529T3 (enExample)
PT (1) PT3356529T (enExample)
RS (1) RS62523B1 (enExample)
SG (1) SG10202008530TA (enExample)
SI (1) SI3356529T1 (enExample)
SM (1) SMT202100622T1 (enExample)
TN (1) TN2018000094A1 (enExample)
TW (3) TWI784934B (enExample)
UA (1) UA121998C2 (enExample)
UY (1) UY36926A (enExample)
WO (1) WO2017059223A2 (enExample)
ZA (1) ZA202106265B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718133B2 (en) 2003-10-09 2010-05-18 3M Innovative Properties Company Multilayer processing devices and methods
KR102348425B1 (ko) * 2016-03-07 2022-01-10 애로우헤드 파마슈티컬스 인코포레이티드 치료용 화합물을 위한 표적화 리간드
US10294474B2 (en) 2016-09-02 2019-05-21 Arrowhead Pharmaceuticals, Inc. Targeting ligands
EP3607069B1 (en) 2017-04-05 2022-11-02 Silence Therapeutics GmbH Products and compositions
JP2020526192A (ja) * 2017-07-06 2020-08-31 アローヘッド ファーマシューティカルズ インコーポレイテッド アルファ−ＥＮａＣの発現を阻害するためのＲＮＡｉ剤、および使用方法
US10597657B2 (en) * 2017-09-11 2020-03-24 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
CN111343994B (zh) * 2017-09-14 2023-11-21 箭头药业股份有限公司 用于抑制血管生成素-样3 (ANGPTL3)的表达的RNAi剂和组合物以及使用方法
CN111655268B (zh) 2017-10-04 2024-03-26 艾维迪提生物科学公司 核酸-多肽组合物及其用途
AU2018352379A1 (en) * 2017-10-17 2020-06-04 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
KR102553382B1 (ko) * 2017-11-13 2023-07-07 사일런스 테라퓨틱스 게엠베하 세포에서 lpa의 발현을 저해하기 위한 핵산
EP3483270A1 (en) * 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
MY209138A (en) * 2018-09-19 2025-06-24 Arrowhead Pharmaceuticals Inc Rnai agents for inhibiting expression of 17beta-hsd type 13- (hsd17b13), compositions thereof, and methods of use
SI3880818T1 (sl) * 2018-11-13 2023-01-31 Silence Therapeutics Gmbh Nukleinske kisline za inhibiranje izražanja LPA v celici
AU2020289464B2 (en) 2019-06-06 2025-12-04 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
WO2020257194A1 (en) * 2019-06-17 2020-12-24 Alnylam Pharmaceuticals, Inc. Delivery of oligonucleotides to the striatum
CN112442499A (zh) * 2019-08-30 2021-03-05 恩智（广州）医药科技有限公司 一种抑制MCM7的siRNA、组合物及其应用
MX2022007005A (es) 2019-12-09 2022-08-25 Amgen Inc Construcciones de iarn y metodos para inhibir la expresion de lpa.
EP4126967A1 (en) * 2020-03-23 2023-02-08 Amgen Inc. Monoclonal antibodies to chemically-modified nucleic acids and uses thereof
JP7476422B2 (ja) 2020-08-05 2024-04-30 ディセルナ ファーマシューティカルズ インコーポレイテッド Ｌｐａ発現を阻害するための組成物及び方法
CN116490195A (zh) * 2020-10-16 2023-07-25 赛诺菲 用于抑制脂蛋白(a)的RNA组合物和方法
KR20230104200A (ko) * 2020-11-05 2023-07-07 암젠 인크 LPA-표적화된 RNAi 작제물을 이용하여 죽상경화성 심혈관질환을 치료하는 방법
WO2022121959A1 (zh) * 2020-12-09 2022-06-16 纳肽得有限公司 siRNA分子及其在治疗冠状动脉疾病中的应用
EP4237561A1 (en) 2020-12-23 2023-09-06 Argonaute Rna Limited Treatment of cardiovascular disease
CN117836307A (zh) 2021-06-18 2024-04-05 弘景生物科技有限公司 功能化的n-乙酰基半乳糖胺核苷
JP2024532271A (ja) 2021-08-30 2024-09-05 ホンジーン バイオテック コーポレイション 官能化ｎ－アセチルガラクトサミンアナログ
CA3229020A1 (en) 2021-09-14 2023-03-23 Stella Khan Treatment of cardiovascular disease
EP4403633A1 (en) * 2021-09-18 2024-07-24 Genoval Therapeutics Co., Ltd. Lpa inhibitor and use thereof
WO2023114746A1 (en) 2021-12-15 2023-06-22 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
TW202340465A (zh) * 2021-12-16 2023-10-16 大陸商上海拓界生物醫藥科技有限公司 靶向ｌｐａ的ｓｉｒｎａ及綴合物
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
JP2025526074A (ja) * 2022-08-11 2025-08-07 エピジェニック・セラピューティクス・プライベイト・リミテッド エピトープ編集標的のための方法およびその使用
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
WO2024151937A1 (en) * 2023-01-13 2024-07-18 Eli Lilly And Company Therapeutic oligonucleotide-containing pharmaceutical compositions and dosing regimens using the same
CN118773191A (zh) * 2023-04-03 2024-10-15 翰森（上海）健康科技有限公司 靶向LPA基因的RNAi剂及其用途
WO2024222686A1 (zh) * 2023-04-24 2024-10-31 上海京新生物医药有限公司 用于抑制LPA表达的RNAi剂及其应用
WO2024240212A1 (zh) * 2023-05-24 2024-11-28 云合智药（苏州）生物科技有限公司 用于抑制angptl3表达的rnai剂及其应用
AU2024280186A1 (en) * 2023-05-31 2025-12-04 Tuojie Biotech (Shanghai) Co., Ltd. Dsrna targeting lpa and use thereof
WO2024249680A2 (en) * 2023-05-31 2024-12-05 Arrowhead Pharmaceuticals, Inc. Hepatic Delivery Platforms For Multimeric RNAi Agent Conjugates and Methods of Use Thereof
DE102023115075A1 (de) * 2023-06-07 2024-12-12 B.Braun Avitum Ag Schlauchrollenpumpe
WO2025064821A2 (en) 2023-09-21 2025-03-27 Ionis Pharmaceuticals, Inc. Compounds and methods for inhibiting lpa
WO2025082058A1 (zh) * 2023-10-16 2025-04-24 润佳(上海)医药技术有限公司 一种抑制LPA基因表达的dsRNA及其用途
CN120344664A (zh) * 2023-10-27 2025-07-18 北京安龙生物医药有限公司 靶向脂蛋白a的寡核苷酸及其用途
WO2025103391A1 (zh) * 2023-11-15 2025-05-22 北京加科瑞康医药科技有限公司 用于抑制lpa的基因表达的sirna，含其的组合物及其用途
CN120020252A (zh) * 2023-11-17 2025-05-20 纳肽得(青岛)生物医药有限公司 抑制LPA表达的siRNA及其用途
CN120098993A (zh) * 2023-12-05 2025-06-06 广东东阳光药业股份有限公司 一种新型的双链siRNA、其缀合物及其用途
CN120485189B (zh) * 2025-07-16 2025-10-17 北京悦康科创医药科技股份有限公司 靶向调控LPA基因表达的siRNA及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011141703A1 (en) * 2010-05-12 2011-11-17 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
EP1159441B8 (en) 1999-03-10 2008-10-29 Marie Curie Cancer Care Delivery of nucleic acids and proteins to cells
DK1407044T4 (en) * 2000-12-01 2017-12-04 Max-Planck-Gesellschaft Zur Förderung Der Wss E V RNA interference mediating small RNA molecules
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
EP1613348B1 (en) 2003-03-12 2010-06-23 The Arizona Board of Regents on Behalf of the University of Arizona Methods for modulating angiogenesis with apelin compositions
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
EP2061443A4 (en) * 2006-08-18 2013-07-24 Arrowhead Res Corp POLYCONJUGATE FOR IN VIVO ADMINISTRATION OF POLYNUCLEOTIDES
AU2009336191B2 (en) 2008-12-18 2017-08-24 Novo Nordisk A/S Extended dicer substrate agents and methods for the specific inhibition of gene expression
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
JP6137834B2 (ja) 2010-02-24 2017-05-31 アローヘッド ファーマシューティカルズ インコーポレイテッド ｓｉＲＮＡの標的化送達のための組成物
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
US9249179B2 (en) * 2010-12-17 2016-02-02 Arrowhead Madison Inc. Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA
WO2012092373A2 (en) 2010-12-29 2012-07-05 Arrowhead Research Corporation In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
CA2842039A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
PT3301177T (pt) * 2011-11-18 2020-06-29 Alnylam Pharmaceuticals Inc Agentes de arni, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
US8933047B2 (en) 2012-04-18 2015-01-13 Arrowhead Madison Inc. Poly(acrylate) polymers for in vivo nucleic acid delivery
RU2624028C2 (ru) 2012-05-24 2017-06-30 Ионис Фармасьютикалз, Инк. Способы и композиции для модулирования экспрессии аполипопротеина (а)
WO2014134483A2 (en) * 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
CN105378082B (zh) * 2013-05-01 2020-06-09 Ionis制药公司 组合物和方法
WO2016149020A1 (en) * 2015-03-17 2016-09-22 Arrowhead Research Corporation Rna interference agents
MX2017014641A (es) 2015-05-29 2018-01-23 Arrowhead Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
SMT202100020T1 (it) * 2015-07-31 2021-03-15 Alnylam Pharmaceuticals Inc Composizioni di irna di transtiretina (ttr) e relativi metodi d'uso per trattare o prevenire malattie associate a ttr
KR102348425B1 (ko) 2016-03-07 2022-01-10 애로우헤드 파마슈티컬스 인코포레이티드 치료용 화합물을 위한 표적화 리간드

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011141703A1 (en) * 2010-05-12 2011-11-17 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Marija Tadin-Strapps et al., "Development of Lipoprotein(a) siRNAs for Mechanism of Action Studies in Non-Human Primate Models of Atherosclerosis", JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, vol. 8, no. 1, vol. 8, no. 1, pages 44-53. *

Also Published As

Publication number Publication date
IL290566B2 (en) 2023-07-01
WO2017059223A3 (en) 2017-05-11
KR20240162596A (ko) 2024-11-15
JP7116212B2 (ja) 2022-08-09
MY195796A (en) 2023-02-21
AU2022283623B2 (en) 2025-07-10
WO2017059223A9 (en) 2017-08-17
EP3356529A4 (en) 2019-09-04
CY1125263T1 (el) 2023-03-24
IL290566B1 (en) 2023-03-01
BR112018006489A2 (pt) 2018-10-09
JOP20160211B1 (ar) 2021-08-17
WO2017059223A2 (en) 2017-04-06
JOP20210043A1 (ar) 2017-06-16
TWI880645B (zh) 2025-04-11
ES2896298T3 (es) 2022-02-24
HUE055942T2 (hu) 2022-01-28
US9932586B2 (en) 2018-04-03
AU2016331084B2 (en) 2022-09-08
CN108368506A (zh) 2018-08-03
AU2022283623A1 (en) 2023-02-02
AU2016331084A1 (en) 2018-04-19
MX2022013010A (es) 2022-11-09
TN2018000094A1 (en) 2019-07-08
NZ780687A (en) 2025-06-27
PH12018500713A1 (en) 2018-10-15
IL300438A (en) 2023-04-01
US10662427B2 (en) 2020-05-26
EA201890864A1 (ru) 2018-09-28
CL2018000803A1 (es) 2018-08-31
JP6991966B2 (ja) 2022-02-03
HK1259063A1 (en) 2019-11-22
UA121998C2 (uk) 2020-08-25
KR102728481B1 (ko) 2024-11-12
TWI836693B (zh) 2024-03-21
US20200263179A1 (en) 2020-08-20
TW202449154A (zh) 2024-12-16
EA038478B1 (ru) 2021-09-03
AU2025242219A1 (en) 2025-10-23
JP2024009262A (ja) 2024-01-19
SMT202100622T1 (it) 2022-01-10
PL3356529T3 (pl) 2021-12-20
MA43347A (fr) 2018-08-08
US20250115907A1 (en) 2025-04-10
SI3356529T1 (sl) 2022-01-31
LT3356529T (lt) 2021-12-27
IL258333B (en) 2022-03-01
JP2022113835A (ja) 2022-08-04
UY36926A (es) 2017-04-28
IL258333A (en) 2018-05-31
CO2018003678A2 (es) 2018-11-30
TW202332769A (zh) 2023-08-16
KR20180052703A (ko) 2018-05-18
PE20181139A1 (es) 2018-07-17
EP3356529B1 (en) 2021-08-25
EP4029941A1 (en) 2022-07-20
TW201726918A (zh) 2017-08-01
IL290566A (en) 2022-04-01
US20180195070A1 (en) 2018-07-12
RS62523B1 (sr) 2021-11-30
SG10202008530TA (en) 2020-10-29
HRP20211410T1 (hr) 2021-12-24
EP3356529A2 (en) 2018-08-08
JP7442574B2 (ja) 2024-03-04
CA3000397A1 (en) 2017-04-06
NZ741086A (en) 2023-11-24
DK3356529T3 (da) 2021-11-08
MX2018003833A (es) 2018-06-18
US20170096665A1 (en) 2017-04-06
JP2018529732A (ja) 2018-10-11
JP2021087459A (ja) 2021-06-10
PT3356529T (pt) 2021-11-04
CR20180231A (es) 2018-05-31
ZA202106265B (en) 2023-08-30
MA43347B1 (fr) 2021-11-30

Similar Documents

Publication Publication Date Title
TWI784934B (zh) 抑制lpa之基因表現之組合物及方法
JP7741927B2 (ja) １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法
TWI823866B (zh) 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法
CN108064313B (zh) 用于抑制因子xii的基因表达的组合物和方法
US20160272970A1 (en) RNA Interference Agents
JP2024086876A (ja) アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物
HK1259063B (en) Compositions and methods for inhibiting gene expression of lpa
EA048832B1 (ru) Композиции и способы для ингибирования генной экспрессии лпа